A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
- 1 March 2014
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 70 (3) , 489-498.e3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Result of a Prospective, Multicenter StudyAnnals of Dermatology, 2012
- Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopeciaThe Journal of Dermatology, 2011
- 5α‐reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progressionThe Prostate, 2010
- Androgenetic alopecia: Quality-of-life and associated lifestyle patternsInternational Journal of Trichology, 2010
- The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasterideJournal of the American Academy of Dermatology, 2006
- Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2004
- FinasterideDrugs, 1999
- Predominance of type I 5α‐reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis)British Journal of Dermatology, 1998
- The psychological effects of androgenetic alopecia in menJournal of the American Academy of Dermatology, 1992
- Male Pattern Baldness: classification and IncidenceSouthern Medical Journal, 1975